BioCentury | Jun 14, 2017
Distillery Therapeutics

Neurology

...marketed to treat gastric ulcers. The generic nucleoside analog ribavirin is marketed to treat HCV. Enzon Pharmaceuticals Inc....
BioCentury | Sep 14, 2015
Finance

Gaining leverage

...was acquired by Actavis plc , now Allergan plc (NYSE:AGN). In 2013, he invested in Enzon Pharmaceuticals Inc....
BioCentury | May 13, 2015
Company News

Baxter buys Sigma-Tau leukemia portfolio

...year from a Phase II study of calaspargase pegol. Sigma-Tau acquired Oncaspar in 2009 from Enzon Pharmaceuticals Inc....
BioCentury | May 12, 2014
Company News

Enzon infectious news

...the same dividend, voting and liquidation rights as a share of the company's common stock. Enzon...
...PegIntron peginterferon alfa-2b from Merck & Co Inc. (NYSE:MRK, Whitehouse Station, N.J.) to treat hepatitis. Enzon Pharmaceuticals Inc....
BioCentury | Dec 16, 2013
Strategy

Out in the cold

...Interferon beta (MS) Betaseron interferon beta-1b Bayer Express Scripts Interferons (other immunological) PegIntron peginterferon alfa-2b Enzon/Merck...
BioCentury | Dec 16, 2013
Company News

Hologic diagnostic news

...both managing directors at Icahn Capital L.P., as directors. Christodoro is also a director at Enzon Pharmaceuticals Inc....
BioCentury | Nov 11, 2013
Company News

Enzon, Santaris deal

...Santaris reacquired from Enzon rights, data, products and IP related to locked nucleic acid (LNA) platform...
...said the move came after Enzon decided to cease its biotech activities. Earlier this year, Enzon...
...or a development timeframe, and Enzon could not be reached (see BioCentury, Aug. 6, 2012). Enzon Pharmaceuticals Inc....
BioCentury | Sep 5, 2013
Targets & Mechanisms

lncRNA meets the androgen receptor

...in vitro , have certain limitations when utilized in vivo ," he told SciBX . Enzon Pharmaceuticals Inc....
...LNA antisense oligonucleotide, EZN-4176 , in Phase I trials to treat prostate cancer. Last December, Enzon...
...Cain, C. SciBX 6 (34); doi:10.1038/scibx.2013.914 Published online Sept. 5, 2013 Companies and Institutions Mentioned Enzon Pharmaceuticals Inc....
BioCentury | Apr 29, 2013
Financial News

Enzon financial update

...sale of the company or its assets. Enzon retained Lazard in December for the review. Enzon...
...Omontys after receiving postmarketing reports of serious hypersensitivity reactions that can be life-threatening or fatal. Enzon...
...White-house Station, N.J.) "adversely impacted interest in a possible acquisition of the company's royalty portfolio." Enzon...
BioCentury | Apr 29, 2013
Finance

Highlights of weekly biotech stock moves

...million, compared with $8 million in 1Q12. On the week, Dyax was down $1.56 (37%). Enzon Pharmaceuticals Inc....
...the company or its assets. The company reported royalty revenues of $41.5 million in 2012. Enzon...
...In February, Affymax and Takeda recalled Omontys after receiving postmarketing reports of serious hypersensitivity reactions. Enzon...
Items per page:
1 - 10 of 607
BioCentury | Jun 14, 2017
Distillery Therapeutics

Neurology

...marketed to treat gastric ulcers. The generic nucleoside analog ribavirin is marketed to treat HCV. Enzon Pharmaceuticals Inc....
BioCentury | Sep 14, 2015
Finance

Gaining leverage

...was acquired by Actavis plc , now Allergan plc (NYSE:AGN). In 2013, he invested in Enzon Pharmaceuticals Inc....
BioCentury | May 13, 2015
Company News

Baxter buys Sigma-Tau leukemia portfolio

...year from a Phase II study of calaspargase pegol. Sigma-Tau acquired Oncaspar in 2009 from Enzon Pharmaceuticals Inc....
BioCentury | May 12, 2014
Company News

Enzon infectious news

...the same dividend, voting and liquidation rights as a share of the company's common stock. Enzon...
...PegIntron peginterferon alfa-2b from Merck & Co Inc. (NYSE:MRK, Whitehouse Station, N.J.) to treat hepatitis. Enzon Pharmaceuticals Inc....
BioCentury | Dec 16, 2013
Strategy

Out in the cold

...Interferon beta (MS) Betaseron interferon beta-1b Bayer Express Scripts Interferons (other immunological) PegIntron peginterferon alfa-2b Enzon/Merck...
BioCentury | Dec 16, 2013
Company News

Hologic diagnostic news

...both managing directors at Icahn Capital L.P., as directors. Christodoro is also a director at Enzon Pharmaceuticals Inc....
BioCentury | Nov 11, 2013
Company News

Enzon, Santaris deal

...Santaris reacquired from Enzon rights, data, products and IP related to locked nucleic acid (LNA) platform...
...said the move came after Enzon decided to cease its biotech activities. Earlier this year, Enzon...
...or a development timeframe, and Enzon could not be reached (see BioCentury, Aug. 6, 2012). Enzon Pharmaceuticals Inc....
BioCentury | Sep 5, 2013
Targets & Mechanisms

lncRNA meets the androgen receptor

...in vitro , have certain limitations when utilized in vivo ," he told SciBX . Enzon Pharmaceuticals Inc....
...LNA antisense oligonucleotide, EZN-4176 , in Phase I trials to treat prostate cancer. Last December, Enzon...
...Cain, C. SciBX 6 (34); doi:10.1038/scibx.2013.914 Published online Sept. 5, 2013 Companies and Institutions Mentioned Enzon Pharmaceuticals Inc....
BioCentury | Apr 29, 2013
Financial News

Enzon financial update

...sale of the company or its assets. Enzon retained Lazard in December for the review. Enzon...
...Omontys after receiving postmarketing reports of serious hypersensitivity reactions that can be life-threatening or fatal. Enzon...
...White-house Station, N.J.) "adversely impacted interest in a possible acquisition of the company's royalty portfolio." Enzon...
BioCentury | Apr 29, 2013
Finance

Highlights of weekly biotech stock moves

...million, compared with $8 million in 1Q12. On the week, Dyax was down $1.56 (37%). Enzon Pharmaceuticals Inc....
...the company or its assets. The company reported royalty revenues of $41.5 million in 2012. Enzon...
...In February, Affymax and Takeda recalled Omontys after receiving postmarketing reports of serious hypersensitivity reactions. Enzon...
Items per page:
1 - 10 of 607